Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease

Stefan Kiechl ¹, Georg Schett , Gregor Wenning

⁰Department of Neurology, University Clinic, Anichstrasse 35, A-6020 Innsbruck, Austria. Stefan.Kiechl@uibk.ac.at

Circulation +

|

May 1, 2004

View abstract on PubMed

Summary

Osteoprotegerin is a significant independent risk factor for cardiovascular disease and atherosclerosis progression. Higher levels predict increased vascular disease risk and mortality in the general population.

Area Of Science

Cardiovascular Research
Biomarkers
Atherosclerosis

Background

Osteoprotegerin (OPG) is a novel tumor necrosis factor receptor superfamily member.
OPG acts as a decoy receptor for the receptor activator of nuclear factor-kappaB ligand.
Emerging research suggests OPG's role in atherogenesis, requiring epidemiological validation.

Purpose Of The Study

To investigate the epidemiological association between OPG levels and atherosclerosis.
To determine if OPG is an independent risk factor for cardiovascular disease (CVD) and vascular mortality.

Main Methods

Prospective, population-based Bruneck Study (1990-2000).
Assessment of carotid artery atherosclerosis (severity, initiation, progression).
Measurement of serum OPG levels at baseline and follow-up; recording of incident CVD and vascular mortality.

Main Results

Serum OPG correlated with vascular risk factors: age, diabetes, inflammation, infection, and smoking.
OPG levels were significantly associated with carotid atherosclerosis severity and 10-year progression.
High OPG was an independent predictor of incident CVD (RR 2.2) and vascular mortality (RR 3.1).

Conclusions

Osteoprotegerin is an independent risk factor for atherosclerosis progression.
Elevated OPG levels predict incident cardiovascular disease and vascular mortality.

Related Concept Videos